IGC Pharma (FRA:IGS1) COGS-to-Revenue : 0.60 (As of Dec. 2024)

View and export this data going back to 2010. Start your Free Trial

What is IGC Pharma COGS-to-Revenue?

IGC Pharma's Cost of Goods Sold for the three months ended in Dec. 2024 was €0.15 Mil. Its Revenue for the three months ended in Dec. 2024 was €0.25 Mil.

IGC Pharma's COGS to Revenue for the three months ended in Dec. 2024 was 0.60.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. IGC Pharma's Gross Margin % for the three months ended in Dec. 2024 was 40.41%.

IGC Pharma COGS-to-Revenue Historical Data

The historical data trend for IGC Pharma's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGC Pharma COGS-to-Revenue Chart

IGC Pharma Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

COGS-to-Revenue

Get a 7-Day Free Trial

0.97

0.87

0.51

0.46

IGC Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
COGS-to-Revenue	Get a 7-Day Free Trial															0.35	0.42	0.40	0.52	0.60

IGC Pharma COGS-to-Revenue Calculation

IGC Pharma's COGS to Revenue for the fiscal year that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.563	/	1.237
	=	0.46

IGC Pharma's COGS to Revenue for the quarter that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.146	/	0.245
	=	0.60

IGC Pharma (FRA:IGS1) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

IGC Pharma's Gross Margin % for the three months ended in Dec. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0.146 / 0.245
	=	40.41 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

IGC Pharma COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of IGC Pharma's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

IGC Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGC Pharma Inc (FRA:IGS1) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

IGC:USA

Address

10224 Falls Road, Potomac, MD, USA, 20854

Website

https://www.igcinc.us

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

IGC Pharma Headlines

No Headlines